Safety and efficacy of antiestrogens for prevention of breast cancer

American Journal of Health-System Pharmacy

Volumn 57, Issue 14, 2000, Pages 1315-1325

  Reddy, Prabashni ^a,d   Chow, Moses S S ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HARTFORD HOSPITAL   (United States)

^d Drug Information Center   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Clinical studies; Raloxifene; Tamoxifen; Toxicity

Indexed keywords

ANTIESTROGEN; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM;

EID: 0034661584     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.14.1315     Document Type: Review

References (35)

1. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol. 1997; 24(suppl 1):SI-5-19.
2. Howell A. Antiestrogens: future prospects. Oncology. 1997; 11(2, suppl 1):59-64.
3. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer. 1996; 32A:576-88.
4. Litherland S, Jackson IM. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev. 1988; 15:183-94.
5. Erlichman C, Loprinzi CL. Hormonal therapies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott Raven; 1997:395-405.
6. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-17.
7. Powles TJ. Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 1997; 24(suppl 1):SI-48-54.
8. Karydas I, Fentiman IS, Tong D et al. Adjuvant androgen treatment of operable breast cancer - a 20 year analysis. Eur J Surg Oncol. 1987; 13:113-7.
9. Ingle JN, Ahmann DL, Green SJ et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981; 304:16-21.
10. Buzdar A, lonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer. J Clin Oncol. 1996; 14:2000-11.
11. Lipton A, Harvey HA, Santen RJ et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 1982; 42(suppl):3434s-6s.
12. Muss HB, Wells B, Paschold EH et al. Megestrol acetate versus tamoxifen in advanced breast cancer: a 5-year analysis. J Clin Oncol. 1998; 6:1098-106.
13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet. 1998; 351:1451-67.
14. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomised Chemoprevention Trial. Lancet. 1998; 352:98-101.
15. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90:1371-88.
16. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998; 352:93-7.
17. Tamoxifen package insert. Wilmington, DE: Zeneca Pharmaceuticals; 1998 Feb.
18. Chlebowski RT, Collyar DE, Somerfield MR et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999; 17:1939-55.
19. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in post-menopausal women. JAMA. 1999; 281:2189-97.
20. lordan VC, Glusman JE, Eckert S et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in 12,000 postmenopausal women. Paper presented at American Society of Clinical Oncology 34th Annual Meeting. Los Angeles, CA; 1998 May 16-19.
21. Raloxifene package insert. Indianapolis, IN: Eli Lilly; 1997 Oct.
22. Jordan VC. An overview of considerations for the testing of tamoxifen as a prevention for breast cancer. Ann N Y Acad Sci. 1995; 768:141-7.
23. Jaiyesimi IA, Buzdar AU, Decker DA et al. Use of tamoxifen for breast cancer twenty-eight years later. J Clin Oncol. 1995; 13:513-29.
24. Love RR, Newcomb PA, Wiebe DA et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82:1327-32.
25. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. BMJ. 1991; 303:435-7.
26. McDonald CC, Alexander FE, Whyte BW et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ. 1995; 311:977-80.
27. Costantino JP, Kuller LH, Ives DG et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997 89:776-82.
28. Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993; 85:1398-406.
29. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992; 326:852-6.
30. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentration and uterine endometrium in postmenopausal women. N Engl J Med. 1997; 337:1641-7.
31. Jordan VC, Assikis VJ. Endometrial cancer and tamoxifen: clearing up a controversy. Clin Cancer Res. 1995; 1:467-72.
32. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86:527-37.
33. Pavlidis NA, Petris C, Briassoulis E et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer. 1992; 69:2961-4.
34. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81:1879-86.
35. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996; 14:78-84.